Long-term Dynamics of Measles Virus–Specific Neutralizing Antibodies in Children Vaccinated Before 12 Months of Age
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciae537 ↗Kurz gefasst
Kontrollierte klinische Studie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Maaike van der Staak und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Antibodies, Viral, Measles, Measles virus. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Ministry of Health, Welfare, and Sport.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Measles is a highly contagious disease, presenting a significant risk for unvaccinated infants and adults. Measles vaccination under the age of 12 months provides early protection but has also been associated with blunting of antibody responses to subsequent measles vaccinations and assumed to have lower vaccine effectiveness.
Methods
Our study included children who received an early measles, mumps, and rubella (MMR) vaccination between 6 and 12 months of age (n = 79, given in addition to the regular MMR vaccination schedule at 14 months and 9 years) and a group without additional early vaccination (n = 44). We evaluated measles virus (MeV)–specific neutralizing antibodies before vaccination at 14 months and up to 6 years thereafter using a plaque reduction neutralization test according to the standard set by the World Health Organization.
Results
We found a significant association between age of first MMR and MeV-specific neutralizing antibody levels later in life. Although most children who received early vaccination seroconverted after the first dose, children vaccinated before 8.5 months of age exhibited a markedly faster antibody decay and lost their protective neutralizing antibody levels over 6 years.
Conclusions
Routine vaccination of infants under 8.5 months of age may lead to blunted MeV-specific antibody responses to subsequent MMR vaccination. Early MMR vaccination should only be considered during measles outbreaks or in other situations of increased risk of MeV infection. Clinical Trials Registration. EudraCT 2013-003078-28.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
- Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
ORCID-Profile: Maaike van der Staak, Alina M Nicolaie, Rik L de Swart, Jelle de Wit, Nynke Y Rots, Robert S van Binnendijk
Förderung
- Dutch Ministry of Health, Welfare, and Sport
Zitieren
APA
van der Staak, M., Ten Hulscher, H. I., Nicolaie, A. M., Smits, G. P., de Swart, R. L., de Wit, J., Rots, N. Y., & van Binnendijk, R. S. (2025). Long-term Dynamics of Measles Virus–Specific Neutralizing Antibodies in Children Vaccinated Before 12 Months of Age. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae537
Vancouver
van der Staak M, Ten Hulscher HI, Nicolaie AM, Smits GP, de Swart RL, de Wit J, et al. Long-term Dynamics of Measles Virus–Specific Neutralizing Antibodies in Children Vaccinated Before 12 Months of Age. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciae537
BibTeX
@article{vanderStaak2025,
author = {van der Staak, Maaike and Ten Hulscher, Hinke I and Nicolaie, Alina M and Smits, Gaby P and de Swart, Rik L and de Wit, Jelle and Rots, Nynke Y and van Binnendijk, Robert S},
title = {Long-term Dynamics of Measles Virus–Specific Neutralizing Antibodies in Children Vaccinated Before 12 Months of Age},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciae537}
}
EUVIMED